Answers are grounded in this paper and cite their sources.
The risk of developing new onset type 2 diabetes appears to be higher in men with benign prostatic hyperplasia exposed to 5α-reductase inhibitors than in men receiving tamsulosin, but did not differ between men receiving dutasteride and those receiving finasteride. Additional monitoring might be required for men starting these drugs, particularly in those with other risk factors for type 2 diabetes.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: